Life Cycle Investment Partners Ltd Invests $38.54 Million in argenex SE $ARGX

Life Cycle Investment Partners Ltd bought a new position in argenex SE (NASDAQ:ARGX) in the 4th quarter, according to its most recent disclosure with the SEC. The firm bought 45,826 shares of the company’s stock, valued at approximately $38,537,000.

Several other institutional investors and hedge funds have also recently modified their holdings of ARGX. Abound Wealth Management lifted its position in shares of argenex by 3,200.0% in the 4th quarter. Abound Wealth Management now owns 33 shares of the company’s stock worth $28,000 after purchasing an additional 32 shares during the period. Sound Income Strategies LLC purchased a new position in argenex in the fourth quarter worth about $28,000. Ameriflex Group Inc. purchased a new position in argenex in the third quarter worth about $32,000. Sunbelt Securities Inc. bought a new stake in shares of argenex in the third quarter worth approximately $36,000. Finally, Aventura Private Wealth LLC bought a new stake in shares of argenex in the fourth quarter worth approximately $38,000. 60.32% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Zacks Research upgraded shares of argenex from a “strong sell” rating to a “hold” rating in a research report on Friday, February 20th. Oppenheimer lowered their target price on shares of argenex from $1,060.00 to $1,014.00 and set an “outperform” rating on the stock in a report on Thursday, April 2nd. Robert W. Baird upped their price target on shares of argenex from $858.00 to $867.00 and gave the company a “neutral” rating in a research note on Friday, February 27th. Wells Fargo & Company upped their price target on shares of argenex from $1,247.00 to $1,260.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Finally, HC Wainwright upped their price target on shares of argenex from $915.00 to $940.00 and gave the company a “buy” rating in a research note on Friday, February 27th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $1,017.78.

argenex Price Performance

Shares of argenex stock opened at $806.46 on Friday. argenex SE has a 1 year low of $510.05 and a 1 year high of $934.62. The firm’s 50-day moving average is $767.17 and its two-hundred day moving average is $815.87. The stock has a market cap of $49.90 billion, a price-to-earnings ratio of 35.91, a PEG ratio of 1.28 and a beta of 0.46.

argenex (NASDAQ:ARGX) last issued its earnings results on Tuesday, March 31st. The company reported $5.52 earnings per share (EPS) for the quarter. The company had revenue of $1.31 billion for the quarter. argenex had a net margin of 31.31% and a return on equity of 33.28%. On average, equities analysts expect that argenex SE will post 25.27 earnings per share for the current year.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.